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Introduction
Triple-negative breast cancer (TNBC) is characterised by
the absence of estrogen receptor (ER), progesterone recep-
tor (PR) and the HER-2 receptor. TNBC is typically asso-
ciated with a poor prognosis due to aggressive tumour
phenotypes, partial response to chemotherapy, and current
lack of clinically validated targeted therapies. Insulin-like
growth factors (IGFs) stimulate cell proliferation and pro-
mote cell survival via receptor phosphorylation and activa-
tion of adaptor proteins such as mitogen-activated protein
kinase (MAPK), and Akt. The overall aim of this project
was to characterise the expression and activation of the
IGF signalling pathway in the MDA-MB-231 TNBC cell
line.
Methods
Expression of steroid and growth hormones and activation
of the IGF signalling pathway in MDA-MB-231 cells was
analysed by western blotting, while expression of PAPP-A
was detected by PCR. The effect of stimulation with IGF1
or inhibition of EGFR/IGF1R tyrosine kinase activity on
proliferation was determined by the MTS cell proliferation
assay. Proliferation was expressed relative to untreated
controls, and data was analysed by ANOVA with Tukey’s
multiple comparison post hoc test.
Results
MDA-MB-231 cells express epidermal growth factor
receptor (EGFR) and low levels of HER3, and were con-
firmed as negative for ER, PR and HER2. IGFBP4 inhibits
IGF1 activity but cleavage by pregnancy associated
plasma protein A (PAPP-A) protease releases active
IGF1. MDA-MB-231 cells express high levels of insulin-
like growth factor binding protein 4 (IGFBP4), and low
levels of PAPP-A. Moreover, MDA-MB-231 cells express
type I IGF1 receptor and proteins along the IGF signal-
ling cascade; namely, Erk and Akt. The presence of phos-
phorylated forms of these proteins shows activation of
the IGF1R signal transduction pathway in MDA-MB-231
cells. Proliferation was increased by IGF1 (E3R) (recom-
binant IGF1, resistant to binding by IGFBPs). Inhibition
of EGFR tyrosine kinase activity or IGF1R tyrosine kinase
activity inhibited proliferation of MDA-MB-231 cells and
a similar effect was observed with dual inhibitors of
PI3K/mTOR or Akt/ P70S6K.
Conclusions
These results suggest that the IGF1 signalling pathway is
activated in MDA-MB-231 TNBC cells. Therefore, inhi-
bition of the IGF1R and/or its downstream targets may
be of benefit in the treatment of TNBC.
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